Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
Lipoprotein(a) May be Falsely Lowered When Troponin T is Elevated
Author(s): Colin Yeo , Xuan Han Koh , Weien Chow , et al Added: 9 months ago

MI/ACS

Prevention & Chronic Conditions
AHA 24 Late-Breaking Discussion: The ZODIAC Trial
Author(s): Harriette Van Spall , Kausik Ray Added: 1 year ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising… View more

Prevention & Chronic Conditions

MI/ACS
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
Hyperkalaemia in Acute Heart Failure: An Asian Population Study
Author(s): Wy Jin Quah , Maizatu Akma Sulong , Ghazali Ahmad , et al Added: 7 months ago

Cardiovascular Renal Metabolic
Spironolactone versus Eplerenone for Resistant Hypertension
Author(s): Hanselim Lim , Wuri Noviar Hamdani Added: 1 year ago

Prevention & Chronic Conditions
New ESC Guidelines for the Management of Hypertension
Author(s): Rhian Touyz Added: 1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only… View more

Prevention & Chronic Conditions
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 8 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
BPROAD: Promising Results for Intensive Blood Pressure Control in Type 2 Diabetes Patients
Added: 1 year ago Source:  Radcliffe CVRM
AUTHOR: Sean DelaneyAmerican Heart Association, 16 Nov, 2024 –Outcomes from theBPROAD (National Key R&D ProgramofChina; NCT03808311) trial revealed that lowering high systolic blood pressure (SBP) with an intensive treatment strategy in patients with type 2 diabetes reduced the risk of major cardiovascular disease as opposed to a standard treatment strategy.Just under 13,000 patients across China… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
New Horizons in Dyslipidaemia 2026
Added: 4 weeks ago Source:  Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the… View more

Guidelines & Statements

Prevention & Chronic Conditions